Advertisement

The effect of androgen administration on in vitro fertilization outcome in poor responders undergoing ovarian stimulation with microdose protocol: A randomized clinical trial

Published:September 29, 2022DOI:https://doi.org/10.1016/j.ejogrb.2022.09.027

      Abstract

      Objective(s)

      Patients with poor ovarian response who have reduced ovarian reserve sometimes despite the maximum dose of gonadotropins do not respond properly. Androgens have been shown to play an important role in the early follicular development and proliferation of granulosa cells. This study aimed to evaluate the effect of androgen administration on IVF outcome in poor responders.

      Study Design

      In this randomized clinical trial, 60 poor responder women candidate for controlled ovarian stimulation were randomly enrolled in two groups (n = 30/each). In the intervention group testosterone gel added to the interrupted microdose flare protocol. The control group received the conventional microdose flare protocol.

      Results

      The main outcome was clinical and chemical pregnancy; and the second outcomes were the number of mature oocytes, duration of cycle and total dose of gonadotropins. Basic clinical and demographic features were comparable between the groups. The total gonadotropin consumption were significantly higher in the control group than the intervention group (p = 0.047). In addition, the number of MII oocytes was higher (but not significant) in the intervention group than the control group (p = 0.16). The mean total duration of the cycle was equal in both groups. There were no significant differences in chemical and clinical pregnancy rates between the two groups (p = 0.41, p = 0.67).

      Conclusion(s)

      The results of the current study showed that androgen administration in poor responders in in vitro fertilization reduces the total dose of gonadotropin, but it does not improve the pregnancy outcomes.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • Mitri F.
        • Behan L.A.
        • Murphy C.A.
        • Hershko-Klement A.
        • Casper R.F.
        • Bentov Y.
        Microdose flare protocol with interrupted follicle stimulating hormone and added androgen for poor responders—an observational pilot study.
        Fertil Steril. 2016; 105: 100-105.e6
        • González-Comadran M.
        • Durán M.
        • Sola I.
        • Fábregues F.
        • Carreras R.
        • Checa M.A.
        Effects of transdermal testosterone in poor responders undergoing IVF: systematic review and meta-analysis.
        Reproductive Biomed Online. 2012; 25: 450-459
        • Bosdou J.K.
        • Venetis C.A.
        • Dafopoulos K.
        • Zepiridis L.
        • Chatzimeletiou K.
        • Anifandis G.
        • et al.
        Transdermal testosterone pretreatment in poor responders undergoing ICSI: a randomized clinical trial.
        Hum Reprod. 2016; 31: 977-985https://doi.org/10.1093/humrep/dew028
        • Ebrahimi M.
        • Akbari-Asbagh F.
        • Ghalandar-Attar M.
        Letrozole+ GnRH antagonist stimulation protocol in poor ovarian responders undergoing intracytoplasmic sperm injection cycles: an RCT.
        Int J Reprod BioMed. 2017; 15: 101-108
        • Gizzo S.
        • Andrisani A.
        • Noventa M.
        • Manfè S.
        • Oliva A.
        • Gangemi M.
        • et al.
        Recombinant LH supplementation during IVF cycles with a GnRH-antagonist in estimated poor responders: a cross-matched pilot investigation of the optimal daily dose and timing.
        Mol Med Rep. 2015; 12: 4219-4229https://doi.org/10.3892/mmr.2015.3904
        • Adashi E.Y.
        • Rohan R.M.
        Intraovarian regulation peptidergic signaling systems.
        Trends Endocrinol Metab. 1992; 3: 243-248
        • Tarlatzis B.
        • Zepiridis L.
        • Grimbizis G.
        • Bontis J.
        Clinical management of low ovarian response to stimulation for IVF: a systematic review.
        Human Reprod Update. 2003; 9: 61-76https://doi.org/10.1093/humupd/dmg007
        • Miell J.P.
        • Taylor A.M.
        • Jones J.
        • Holly J.M.P.
        • Gaillard R.C.
        • Pralong F.P.
        • et al.
        The effects of dexamethasone treatment on immunoreactive and bioactive insulin-like growth factors (IGFs) and IGF-binding proteins in normal male volunteers.
        J Endocrinol. 1993; 136: 525-533
        • Smith M.P.
        • Mathur R.S.
        • Keay S.D.
        • Hall L.
        • Hull M.G.
        • Jenkins J.M.
        Periovulatory human oocytes, cumulus cells, and ovarian leukocytes express type 1 but not type 2 11β-hydroxysteroid dehydrogenase RNA.
        Fertil Steril. 2000; 73: 825-830
        • Aflatoonian A.
        • Lotfi M.
        • Saeed L.
        • Tabibnejad N.
        Effects of intraovarian injection of autologous platelet-rich plasma on ovarian rejuvenation in poor responders and women with primary ovarian insufficiency.
        Reprod Sci. 2021; 28: 2050-2059https://doi.org/10.1007/s43032-021-00483-9
        • Balasch J.
        • Fábregues F.
        • Peñarrubia J.
        • Carmona F.
        • Casamitjana R.
        • Creus M.
        • et al.
        Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH.
        Hum Reprod. 2006; 21: 1884-1893https://doi.org/10.1093/humrep/del052
        • Kim C.-H.
        • Howles C.M.
        • Lee H.-A.
        The effect of transdermal testosterone gel pretreatment on controlled ovarian stimulation and IVF outcome in low responders.
        Fertil Steril. 2011; 95: 679-683
        • Massin N.
        • Cedrin-Durnerin I.
        • Coussieu C.
        • Galey-Fontaine J.
        • Wolf J.
        • Hugues J.-N.
        Effects of transdermal testosterone application on the ovarian response to FSH in poor responders undergoing assisted reproduction technique—a prospective, randomized, double-blind study.
        Hum Reprod. 2006; 21: 1204-1211https://doi.org/10.1093/humrep/dei481
        • Fabregues F.
        • Penarrubia J.
        • Creus M.
        • Manau D.
        • Casals G.
        • Carmona F.
        • et al.
        Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial.
        Hum Reprod. 2009; 24: 349-359https://doi.org/10.1093/humrep/den428
        • Doan H.T.
        • Quan L.H.
        • Nguyen T.T.
        The effectiveness of transdermal testosterone gel 1% (androgel) for poor responders undergoing in vitro fertilization.
        Gynecol Endocrinol. 2017; 33: 977-979https://doi.org/10.1080/09513590.2017.1332586
        • Keay S.
        • Liversedge N.
        • Mathur R.
        • Jenkins J.
        Assisted conception following poor ovarian response to gonadotrophin stimulation.
        BJOG: Int J Obstetr Gynaecol. 1997; 104: 521-527
        • Sipe C.S.
        • Thomas M.R.
        • Stegmann B.J.
        • Van Voorhis B.J.
        Effects of exogenous testosterone supplementation in gonadotrophin stimulated cycles.
        Hum Reprod. 2010; 25: 690-696https://doi.org/10.1093/humrep/dep442
        • Haydardedeoglu B.
        • Isik A.
        • Kilicdag E.
        The combination of dhea, transdermal testosterone and growth hormone as an adjuvant therapy in assisted reproductive technology in patients with dor below 40 years of age.
        Fertil Steril. 2014; 102: e221-e222
        • Saharkhiz N.
        • Zademodares S.
        • Salehpour S.
        • Hosseini S.
        • Nazari L.
        • Tehrani H.G.
        The effect of testosterone gel on fertility outcomes in women with a poor response in in vitro fertilization cycles: a pilot randomized clinical trial.
        J Res Med Sci. 2018; 23: 3